Tirzepatide after CBT-T achieved binge-eating disorder remission and 39-pound weight loss in a single patient.
Background
Patients with binge-eating disorder (BED) and obesity often seek weight loss alongside eating disorder treatment. Current standard-of-care, such as cognitive-behavioural therapy (CBT), effectively addresses eating disorder behaviors but may not always achieve significant weight reduction. Glucose-dependent insulinotropic polypeptide/glucagon-like-peptide receptor agonists (GIP/GLP-1s) are potent agents for weight loss and glycemic control, primarily by suppressing appetite and reducing energy intake. However, their utility and safety in patients with active or remitted eating disorders, particularly regarding potential risks of disordered eating, remain largely unexplored, creating a critical gap in treatment strategies.
Study Design
This single-case experimental design study investigated the effects of Tirzepatide 7.5 mg/0.05 mL following 10-session cognitive-behavioural therapy (CBT-T) in a 37-year-old female patient diagnosed with BED and severe obesity (BMI of 68.9 kg/m2). The study comprised two sequential treatment phases: 3 months of CBT-T, followed by 9 months of GIP/GLP-1 administration. Researchers assessed eating disorder behaviors and cognitions weekly, then monthly, using the Eating Disorder 15 (ED-15) questionnaire across both phases to monitor progress and outcomes.
Results
The initial 3-month CBT-T phase successfully reduced both eating disorder cognitions and binge frequency, aligning with the study's hypothesis. Following this, during the 9-month GIP/GLP-1 administration phase, binge frequency remained consistently low, and dietary restraint was notably absent, also as hypothesized. The patient experienced continued reductions in overall eating disorder cognitions. Most significantly, the intervention led to a substantial 39-pound weight loss. No serious adverse events were reported throughout the GIP/GLP-1 treatment period, suggesting good tolerability. This case highlights a potential synergy between psychotherapy and pharmacological intervention.
Tirzepatide use after CBT-T was followed by eating disorder remission and a 39-pound weight loss without serious adverse events.
Key Findings
- CBT-T reduced eating disorder cognitions and binge frequency.
- Tirzepatide maintained low binge frequency after CBT-T.
- Dietary restraint remained absent during Tirzepatide use.
- Tirzepatide led to a 39-pound weight loss.
- No serious adverse events were observed with Tirzepatide.
Why It Matters
This case report suggests that Tirzepatide, when used after psychotherapy, may be a safe and effective option for individuals with binge-eating disorder and obesity, potentially leading to both ED remission and significant weight loss. For peptide users and clinicians, this indicates a potential protocol where foundational behavioral therapy (like CBT-T) could precede or accompany GIP/GLP-1 agonist use, possibly mitigating risks of disordered eating that might arise from appetite suppression alone. The 7.5 mg/0.05 mL dose of Tirzepatide was well-tolerated, offering a starting point for further research into combined treatment strategies. This approach could transform how BED and obesity are managed, moving towards integrated care models.
tirzepatide
binge-eating-disorder
obesity
glp-1-agonist
gip-agonist
weight-loss